GNTA - היקף יתרות המזומנים של החברה genenta.com

סמל תאגידי ולוגו של Genenta Science S.p.A. (GNTA)

Genenta Science S.p.A. (GNTA) is developing a unique genetic brain defense using stem cells and patented tumor-fighting methods. The organization's cash balances clearly illustrate the financial dynamics, where 0.02 records the value of this parameter. Meanwhile, production and testing have been outsourced to external contractors, and the R&D stage for solid tumors is temporarily increasing unit costs during the scaling of research.

Genenta Science - יתרת המזומנים של החברה GNTA (תקופה 04.07.2022 - 04.11.2026)

פילוחי מדדים פיננסיים ומדדי שוק עבור Genenta Science S.p.A. (GNTA)

- שווי מניות ותחזית קונצנזוס למחירים:
- פרטי פוזיציית מזומנים ותזרימי מזומנים:
ניתוח כל מדדי החברה:GNTA Genenta Science S.p.A.
פריט של המותג Genenta

As an innovative leader in gene therapy for solid tumors, Genenta Science S.p.A. (GNTA) requires significant R&D capital expenditures, making the volume of liquid assets a critical factor for survival. This metric measures the total balance of cash and cash equivalents, allowing for an assessment of the company's ability to cover operating expenses without incurring external debt. By analyzing changes in cash reserves, an investor can timely identify the risk of a liquidity gap or an inefficient capital surplus.